Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.50 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.50 |
| ▸ | SSTR5 | P35346 | 7/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | SCD | O00767 | 1/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3952272 | 0.92 | OPRK1 (0.59) | OPRK1PDE10APCSK9SSTR5ELANE | |
| SCHEMBL16666111 | 0.86 | ELANE (0.62) | OPRK1PDE10APCSK9SSTR5ELANE | |
| SCHEMBL5065261 | 0.84 | ELANE (0.65) | OPRK1PDE10APCSK9SSTR5ELANE | |
| SCHEMBL12966291 | 0.84 | OPRK1 (0.53) | OPRK1PDE10APCSK9SSTR5ELANE | |
| SCHEMBL3577272 | 0.82 | OPRK1 (0.53) | OPRK1PDE10APCSK9SSTR5ELANE | |
| SCHEMBL13564111 | 0.81 | OPRK1 (0.53) | OPRK1PDE10APCSK9SSTR5ELANE | |
| SCHEMBL13564156 | 0.81 | OPRK1 (0.50) | OPRK1PDE10APCSK9SSTR5ELANE | |
| SCHEMBL13563397 | 0.81 | OPRK1 (0.53) | OPRK1PDE10APCSK9SSTR5CXCR3 | |
| SCHEMBL21815043 | 0.81 | ESR1 (0.43) | SSTR5HDAC6 | |
| SCHEMBL15014110 | 0.81 | OPRK1 (0.53) | OPRK1PDE10APCSK9SSTR5CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280703-A1 | Heteroaryloxycarbocyclyl Compounds as PDE 10 Inhibitors | AMGEN INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280703-A1 | Heteroaryloxycarbocyclyl Compounds as PDE 10 Inhibitors | AMGEN INC. | 2016-09-29 | — | — | US | disclosed |
| US-8952037-B2 | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952037-B2 | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20110306591-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | INC., AMGEN | 2011-12-15 | — | — | US | disclosed |
| US-20110306591-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | INC., AMGEN | 2011-12-15 | — | — | US | disclosed |
| WO-2011143366-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306591-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | PDE10A, PDE9A, HDAC10 | OPRK1 1351/4885PDE10A 1/4885PCSK9 171/4885 |
| US-20160280703-A1 | Heteroaryloxycarbocyclyl Compounds as PDE 10 Inhibitors | PDE10A, PDE9A, PDE7A | OPRK1 1357/4885PDE10A 1/4885PCSK9 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.